Tactics to avoid inhibition of cytochrome P450s

Topics in Medicinal Chemistry

Volumn 9, Issue , 2014, Pages 107-158

  Leach, Andrew G ^a  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Cytochrome p450; Inhibition; Lead optimization; Medicinal chemistry

Indexed keywords

ABIRATERONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ECONAZOLE; FLUCONAZOLE; HEME; IRON; METYRAPONE; PRINOMASTAT;

ARTICLE; CHELATION; CRYSTAL STRUCTURE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; LIPOPHILICITY; METAL BINDING; MOLECULAR WEIGHT; PROTEIN STRUCTURE; QUANTUM MECHANICS;

EID: 84916198560     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/7355_2013_25     Document Type: Article

References (114)

1. Li AP (2008) Drug–drug interactions in pharmaceutical development. Wiley New York; Chichester
2. Guengerich FP (2005) Human cytochrome P450 enzymes. In: Ortiz de Montellano PR (ed) Cytochrome P450: structure, mechanism, and biochemistry, 3rd edn. New York: Kluwer Academic/Plenum, pp 377–530
3. Obach RS (2008) In inhibition of drug-metabolizing enzymes and drug-drug interactions in drug discovery and development. Pharmacology 75–93
4. Bibi Z (2008) Role of cytochrome P450 in drug interactions. Nutr Metab 5:27
5. Po AL, Zhang WY (1998 Jun 20) What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 351(9119):1829–1830
6. Tung RD, Chandorkar G, Perni RB, inventors (2005) Anonymous pharmaceutical compositions comprising HCV NS3/4A protease inhibitor and cytochrome P 450 monooxygenase inhibitor for HCV treatment. WO2005042020A2. 200505/12
7. Norbeck DW, Kempf DJ, Leonard JM, Bertz RJ, inventors (1997) Anonymous use of ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating aids. WO9701349A1. 199701/16
8. Lumpkin MM, Alpert S (2012) Risk of drug interactions with St. John’s Wort and Indinavir and other Drugs. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ ucm052238.htm. Accessed 10 September 2012
9. Morgan ET (2001 March 01) Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab Dispos 29(3):207–212
10. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 23(1–3):3–25
11. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discovery 6(11):881–890
12. Gleeson MP (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 51(4):817–834
13. Hann MM (2011) Molecular obesity, potency and other addictions in drug discovery. Med Chem Commun 2(5):349–355
14. Testa B, Jenner P (1981) Inhibitors of cytochrome P-450s and their mechanism of action. Drug Metab Rev 12(1):1–117
15. Adams JL, Boehm JC, Kassis S, Gorycki PD, Webb EF, Hall R et al (1998) Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg Med Chem Lett 8(22):3111–3116
16. Laufer SA, Hauser DRJ, Domeyer DM, Kinkel K, Liedtke AJ (2008) Design, synthesis, and biological evaluation of novel tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme’s surface-exposed front region. J Med Chem 51(14):4122–4149
17. Ekroos M, Sjoegren T (2006) Structural basis for ligand promiscuity in cytochrome P 450 3A4. Proc Natl Acad Sci USA 103(37):13682–13687
18. Sevirioukova IF, Poulos TL (2010) Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci USA 1–6:6
19. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-. ANG. resolution. J Biol Chem 279(37):38091–38094
20. Bren U, Oostenbrink C (2012) Cytochrome P450 3A4 inhibition by ketoconazole: tackling the problem of ligand cooperativity using molecular dynamics simulations and free-energy calculations. J Chem Inf Model 52(6):1573–1582
21. Williams PA, Cosme J, Ward A, Angove HC, Matak VD, Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424(6947):464–468
22. Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD et al (2004) The structure of human cytochrome P 450 2C9 complexed with flurbiprofen at 2.0-.ANG. resolution. J Biol Chem 279(34):35630–35637
23. Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD et al (2007) Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 282(19):14348–14355
24. Porubsky PR, Meneely KM, Scott EE (2008 November 28) Structures of human cytochrome P-450 2E1. J Biol Chem 283(48):33698–33707
25. Porubsky PR, Battaile KP, Scott EE (2010) Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode. J Biol Chem 285 (29):22282–22290
26. DeVore NM, Meneely KM, Bart AG, Stephens ES, Battaile KP, Scott EE (2012) Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine. FEBS J 279 (9):1621–1631
27. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK et al (2006) Crystal structure of human cytochrome P 450 2D6. J Biol Chem 281(11):7614–7622
28. Wang A, Savas U, Hsu M, Stout CD, Johnson EF (2012 March 30) Crystal structure of human cytochrome P450 2D6 with prinomastat bound. J Biol Chem 287(14):10834–10843
29. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF (2004 March 05) Structure of human microsomal cytochrome P450 2C8. J Biol Chem 279(10):9497–9503
30. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF (2008 June 20) Determinants of cytochrome P450 2C8 substrate binding. J Biol Chem 283(25):17227–17237
31. DeVore NM, Smith BD, Urban MJ, Scott EE (2008) Key residues controlling phenacetin metabolism by human cytochrome P450 2A Enzymes. Drug Metab Dispos 36 (12):2582–2590
32. Sansen S, Hsu M, Stout CD, Johnson EF (2007) Structural insight into the altered substrate specificity of human cytochrome P450 2A6 mutants. Arch Biochem Biophys 464(2):197–206
33. Yano JK, Hsu MH, Griffin KJ, Stout CD, Johnson EF (2005 Sep) Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 12(9):822–823
34. Leach AG, Kidley NJ (2011) Quantitatively interpreted enhanced inhibition of cytochrome P450s by heteroaromatic rings containing nitrogen. J Chem Inf Model 51:1048–1063
35. Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14(6):611–650
36. Oxidative, reductive, and hydrolytic metabolism of drugs. Section Title: Pharmacology; 2008.
37. Rittle J, Green MT (2010 November 12) Cytochrome P450 compound I: capture, characterization, and C–H bond activation kinetics. Science 330(6006):933–937
38. Sligar SG (2010) Glimpsing the critical intermediate in cytochrome P450 oxidations. Science 330(6006):924–925
39. Meunier B, de Visser SP, Shaik S (2004) Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes. Chem Rev (Washington, DC) 104(9):3947–3980
40. Newcomb M, Toy PH (2000 Jul) Hypersensitive radical probes and the mechanisms of cytochrome P450-catalyzed hydroxylation reactions. Acc Chem Res 33(7):449–455
41. Shaik S, Kumar D, de Visser SP, Altun A, Thiel W. Theoretical perspective on the structure and mechanism of cytochrome P 450 enzymes. Chem Rev (Washington, DC) 105 (6):2279–2328
42. Shaik S, Cohen S, Wang Y, Chen H, Kumar D, Thiel W (2010) P 450 Enzymes: their structure, reactivity, and selectivity – modeled by QM/MM calculations. Chem Rev (Washington, DC) 110(2):949–1017
43. Afzelius L, Arnby CH, Broo A, Carlsson L, Isaksson C, Jurva U et al (2007) State-of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistical insights, and future applications. Drug Metab Rev 39(1):61–86
44. Refsgaard HHF, Jensen BF, Christensen IT, Hagen N, Brockhoff PB (2006) In silico prediction of cytochrome P450 inhibitors. Drug Dev Res 67(5):417–429
45. Viswanadhan VN, Ghose AK, Revankar GR, Robins RK (1989) Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 29(3):163–172
46. Ritchie TJ, Macdonald SJF, Peace S, Pickett SD, Luscombe CN (2012) The developability of heteroaromatic and heteroaliphatic rings – do some have a better pedigree as potential drug molecules than others? Med Chem Commun 3(9):1062–1069
47. Ritchie TJ, Macdonald SJ (2009 Nov) The impact of aromatic ring count on compound developability–are too many aromatic rings a liability in drug design? Drug Discov Today 14 (21–22):1011–1020
48. Ritchie TJ, Macdonald SJ, Young RJ, Pickett SD (2011 Feb) The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov Today 16(3–4):164–171
49. Lovering F, Bikker J, Humblet C (2009) Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem 52(21):6752–6756
50. Sun H, Veith H, Xia M, Austin CP, Huang R (2011) Predictive models for cytochrome P450 isozymes based on quantitative high throughput screening data. J Chem Inf Model 51 (10):2474–2481
51. Veith H, Southall N, Huang R, James T, Fayne D, Artemenko N et al (2009 Nov) Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. Nat Biotechnol 27(11):1050–1055
52. Waring MJ (2010) Lipophilicity in drug discovery. Expert Opin Drug Discovery 5 (3):235–248
53. Balding PR, Porro CS, McLean KJ, Sutcliffe MJ, Marechal J, Munro AW et al (2008) How do azoles inhibit cytochrome P450 enzymes? a density functional study. J Phys Chem A 112 (50):12911–12918
54. Klingenberg M (1958 Jun) Pigments of rat liver microsomes. Arch Biochem Biophys 75 (2):376–386
55. OMURA T, SATO R (1962 Apr) A new cytochrome in liver microsomes. J Biol Chem 237:1375–1376
56. The Porphyrins vol 3: Physical Chemistry Part A. New York: Academic; 1978.
57. Jefcoate CR (1978) Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. Biomemb C Methods Enzymol 52:258–279
58. Hunter CA (2004) Quantifying intermolecular interactions: guidelines for the molecular recognition toolbox. Angew Chem Int Ed 43(40):5310–5324
59. Hughes JD, Blagg J, Price DA, Bailey S, DeCrescenzo GA, Devraj RV et al (2008) Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 18(17):4872–4875
60. Waring MJ (2009) Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower log D limits based on permeability. Bioorg Med Chem Lett 19(10):2844–2851
61. Scott JS, Birch AM, Brocklehurst KJ, Broo A, Brown HS, Butlin RJ et al (2012 Jun 14) Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation. J Med Chem 55 (11):5361–5379
62. Schenkman JB, Remmer H, Estabrook RW (1967 Mar) Spectral studies of drug interaction with hepatic microsomal cytochrome. Mol Pharmacol 3(2):113–123
63. Attard G, Belldegrun AS, De Bono JS (2005) Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96(9):1241–1246
64. Temple TE, Liddle GW (1970) Inhibitors of adrenal steroid biosynthesis. Annu Rev Pharmacol 10:199–218
65. Ahmad Z, Sharma S, Khuller GK (2006 Aug) Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett 261(2):181–186
66. Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM (2002 Mar) Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab Dispos 30 (3):314–318
67. Riley RJ, Parker AJ, Trigg S, Manners CN (2001 May) Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm Res 18(5):652–655
68. Lowe D (2012) In the pipeline. http://pipeline.corante.com/archives/2012/07/18/ the_best_rings_to_put_in_your_molecules.php. Accessed 19 September 2012
69. Pitt WR, Parry DM, Perry BG, Groom CR (2009) Heteroaromatic rings of the future. J Med Chem 52(9):2952–2963
70. Seward HE, Roujeinikova A, McLean KJ, Munro AW, Leys D (2006 Dec 22) Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode. J Biol Chem 281(51):39437–39443
71. Orr ST, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS et al (2012 Jun 14) Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J Med Chem 55(11):4896–4933
72. Guengerich FP (2008) Cytochrome P450 and chemical toxicology. Chem Res Toxicol 21 (1):70–83
73. Fontana E, Dansette PM, Poli SM (2005 Oct) Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6(5):413–454
74. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M et al (2005) Mechanismbased inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44 (3):279–304
75. Nagashima S, Hondo T, Nagata H, Ogiyama T, Maeda J, Hoshii H et al (2009) Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors. Bioorg Med Chem 17(19):6926–6936
76. Safina BS, Baker S, Baumgardner M, Blaney PM, Chan BK, Chen YH et al (2012 Jun 28) Discovery of novel PI3-kinase delta specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition. J Med Chem 55(12):5887–5900
77. Wu YJ, Davis CD, Dworetzky S, Fitzpatrick WC, Harden D, He H et al (2003 Aug 28) Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. J Med Chem 46(18):3778–3781
78. Walker DP, Bi FC, Kalgutkar AS, Bauman JN, Zhao SX, Soglia JR et al (2008 Dec 1) Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation. Bioorg Med Chem Lett 18(23):6071–6077
79. Meanwell NA (2011) Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem 54(8):2529–2591
80. Sparks SM, Banker P, Bickett DM, Carter HL, Clancy DC, Dickerson SH et al (2009) Anthranilamide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups. Bioorg Med Chem Lett 19(3):976–980
81. Shao L, Hewitt MC, Malcolm SC, Wang F, Ma J, Campbell UC et al (2011) Synthesis and pharmacological characterization of bicyclic 3-aryl octahydrocyclopenta[c]pyrrole analogues as triple reuptake inhibitors. J Med Chem 54(15):5283–5295
82. Naganawa A, Matsui T, Ima M, Saito T, Murota M, Aratani Y et al (2006) Further optimization of sulfonamide analogs as EP1 receptor antagonists: synthesis and evaluation of bioisosteres for the carboxylic acid group. Bioorg Med Chem 14(21):7121–7137
83. Li H, Tatlock J, Linton A, Gonzalez J, Jewell T, Patel L et al (2009) Discovery of (R)-6- cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a] pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J Med Chem 52(5):1255–1258
84. Kaku T, Tsujimoto S, Matsunaga N, Tanaka T, Hara T, Yamaoka M et al (2011) 17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors. Bioorg Med Chem 19(7):2428–2442
85. Kaku T, Matsunaga N, Ojida A, Tanaka T, Hara T, Yamaoka M et al (2011) 17,20-Lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors. Bioorg Med Chem 19(5):1751–1770
86. Iyengar RR, Lynch JK, Mulhern MM, Judd AS, Freeman JC, Gao J et al (2007) An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists. Bioorg Med Chem Lett 17(4):874–878
87. Chen C, Wu D, Guo Z, Xie Q, Reinhart GJ, Madan A et al (2008) Discovery of Sodium R-(+)- 4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6- dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (Elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem 51(23):7478–7485
88. Berlin M, Ting PC, Vaccaro WD, Aslanian R, McCormick KD, Lee JF et al (2006) Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists. Bioorg Med Chem Lett 16(4):989–994
89. Zimmermann K, Wittman MD, Saulnier MG, Velaparthi U, Langley DR, Sang X et al (2008) Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors. Bioorg Med Chem Lett 18(14):4075–4080
90. Wustrow DJ, Maynard GD, Yuan J, Zhao H, Mao J, Guo Q et al (2008) Aminopyrazine CB1 receptor inverse agonists. Bioorg Med Chem Lett 18(11):3376–3381
91. Wood A, Armour D (2005) The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog Med Chem 43:239–271
92. Foti RS, Rock DA, Han X, Flowers RA, Wienkers LC, Wahlstrom JL (2012) Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19. J Med Chem 55 (3):1205–1214
93. Ulmschneider S, Mueller-Vieira U, Mitrenga M, Hartmann RW, Oberwinkler-Marchais S, Klein CD et al (2005) Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem 48(6):1796–1805
94. Lucas S, Heim R, Negri M, Antes I, Ries C, Schewe KE et al (2008) Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem 51(19):6138–6149
95. Gobbi S, Cavalli A, Rampa A, Belluti F, Piazzi L, Paluszcak A et al (2006) Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem 49(15):4777–4780
96. Sparks SM, Banker P, Bickett DM, Clancy DC, Dickerson SH, Garrido DM et al (2009) Anthranilamide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2 Optimization of serine and threonine ether amino acid residues. Bioorg Med Chem Lett 19(3):981–985
97. Min KH, Xia Y, Kim EK, Jin Y, Kaur N, Kim ES et al (2009) A novel class of highly potent multidrug resistance reversal agents: disubstituted adamantyl derivatives. Bioorg Med Chem Lett 19(18):5376–5379
98. Gibson C, Schnatbaum K, Pfeifer JR, Locardi E, Paschke M, Reimer U et al (2009) Novel small molecule bradykinin B2 receptor antagonists. J Med Chem 52(14):4370–4379
99. Zhang X, Tellew JE, Luo Z, Moorjani M, Lin E, Lanier MC et al (2008) Lead optimization of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson’s disease. J Med Chem 51(22):7099–7110
100. Miwa K, Hitaka T, Imada T, Sasaki S, Yoshimatsu M, Kusaka M et al (2011) Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4- dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem 54(14):4998–5012
101. Laufer SA, Zimmermann W, Ruff KJ (2004) Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position. J Med Chem 47(25):6311–6325
102. Holsworth DD, Cai C, Cheng X, Cody WL, Downing DM, Erasga N et al (2006) ketopiperazine-based renin inhibitors: optimization of the "C" ring. Bioorg Med Chem Lett 16(0):2500–2504
103. Degnan AP, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Denton R et al (2008) Discovery of (R)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1Hindazol- 5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1- carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. J Med Chem 51 (16):4858–4861
104. Yuan J, Simpson RD, Zhao W, Tice CM, Xu Z, Cacatian S et al (2011) Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocket. Bioorg Med Chem Lett 21(16):4836–4843
105. Tajima H, Honda T, Kawashima K, Sasabuchi Y, Yamamoto M, Ban M et al (2011) Pyridylmethylthio derivatives as VEGF inhibitors: Part 2. Bioorg Med Chem Lett 21 (4):1232–1235
106. Hartmann RW, Hector M, Wachall BG, Palusczak A, Palzer M, Huch V et al (2000) Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17Iˆ _ -Hydroxylase/C17-20-Lyase (P450 17). J Med Chem 43(23):4437–4445
107. Lucas S, Heim R, Ries C, Schewe KE, Birk B, Hartmann RW (2008) In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives. J Med Chem 51 (24):8077–8087
108. Clement OO, Freeman CM, Hartmann RW, Handratta VD, Vasaitis TS, Brodie AMH et al (2003) Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. J Med Chem 46(12):2345–2351
109. Gianotti M, Botta M, Brough S, Carletti R, Castiglioni E, Corti C et al (2010) Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders. J Med Chem 53(21):7778–7795
110. Sehon CA, Wang GZ, Viet AQ, Goodman KB, Dowdell SE, Elkins PA et al (2008) Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases. J Med Chem 51(21):6631–6634
111. Chen A, Bayly C, Bezencon O, Richard-Bildstein S, Dube D, Dube L et al (2010) Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension. Bioorg Med Chem Lett 20(7):2204–2209
112. Chen A, Aspiotis R, Campeau L, Cauchon E, Chefson A, Ducharme Y et al (2011) Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines. Bioorg Med Chem Lett 21(24):7399–7404
113. Boezio AA, Berry L, Albrecht BK, Bauer D, Bellon SF, Bode C et al (2009) Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. Bioorg Med Chem Lett 19(22):6307–6312
114. Yarnell A (2009) Heavy-hydrogen drugs turn heads, again. Chem Eng News Arch 87 (25):36–39